Dominion Biologicals Limited

Since incorporation in 1972, Dominion Biologicals Limited (DBL) has concentrated on manufacturing and marketing to our health care colleagues five major categories of superior quality blood diagnostic products: Antiglobulin Reagents, Blood Grouping and Typing Reagents, Rare Blood Typing Reagents, Reagent Red Blood Cells (Human) and Quality Control Systems. DBL manufactures all of these products in Canada (Nova Scotia), from production and processing of initial raw materials (human plasma, hybridoma derived monoclonal antibodies and red blood cells) through final filling, labelling and quality control. This maximizes the company’s ability to respond to customer’s needs and provides maximum assurance of product excellence. Dominion Biologicals Limited has established a full integrated research and development department actively engaged in hybridoma research designed to replace human and animal source antibodies with murine and human monoclonal antibodies for use in unique, new immunodiagnostic test systems. DBL is the only immunodiagnostic company in blood banking with comprehensive in-house hybridoma research, development, and production capabilities. Currently, Dominion Biologicals holds the major Canadian Market Share for its products and has a very significant presence in European, Mid-East, South American and Asian markets. The company, through its unique hybridoma research, development and production scale cell culture capabilities, actively pursues mutually beneficial collaborative technology/products development, manufacturing and related technologies, as well as comprehensive diagnostic marketing sales and distribution capabilities in Canada and specific international markets. DBL has become ISO 13485 certified and holds European CE marking registration.

Company’s Keywords: